Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden. Login für vollen Zugriff.

Cardiovascular and renal outcomes with empagliflozin in heart failure

Title:	Cardiovascular and renal outcomes with empagliflozin in heart failure
Authors:	Packer M.; Anker S. D.; Butler J.; Filippatos G.; Pocock S. J.; Carson P.; Januzzi J.; Verma S.; Tsutsui H.; Brueckmann M.; Jamal W.; Kimura K.; Schnee J.; Zeller C.; Cotton D.; Bocchi E.; Bohm M.; Choi D. -J.; Chopra V.; Chuquiure E.; Giannetti N.; Janssens S.; Zhang J.; Gonzalez Juanatey J. R.; Kaul S.; Brunner-La Rocca H. -P.; Merkely B.; Nicholls S. J.; Perrone S.; Pina I.; Ponikowski P.; Sattar N.; Senni M.; Seronde M. -F.; Spinar J.; Squire I.; Taddei S.; Wanner C.; Zannad F.; EMPEROR-Reduced Trial Investigators: D Aizenberg; L Cartasegna; H Colombo; M Fernandez Moutin; J Glenny; C Alvarez Lorio; D Anauch; R Campos; A Facta; A Fernandez; R Ahuad Guerrero; L Lobo Márquez; R A Leon de la Fuente; M Mansilla; M Hominal; E Hasbani; M Najenson; H Luquez; L Guzman; H Sessa; M Amuchástegui; O Salomone; E Perna; D Piskorz; M Sicer; D Perez de Arenaza; C Zaidman; S Nani; C Poy; J Resk; R Villarreal; C Majul; F Colombo Berra; T Smith Casabella; G Carnero; A Caccavo; M Berli; N Budassi; J Bono; A Alvarisqueta; J Amerena; K Kostner; A Hamilton; A Begg; D Colquhoun; A Sverdlov; G Vaddadi; J Wong; J Coller; D Prior; A Friart; A Leone; S Janssens; G Vervoort; P Timmermans; T Sarens; H Vandekerckhove; P Van De Borne; F Chenot; J De Sutter; A Z Maria Middelares; E De Vuyst; P Debonnaire; M Dupont; O Pereira Dutra; L H Canani; M da Consolação Vieira Moreira; W de Souza; L M Backes; L Maia; E R Manenti; F Villaça Guimarães Filho; T Franco Hirakawa; L A Saliba; F C Neuenschwander; C A de Freitas Zerbini; G Gonçalves; Y Gonçalves Mello; J Ascenção de Souza; L Beck da Silva Neto; E A Bocchi; J Da Silveira; M Hernandes; H C Finimundi; C R Sampaio; E Vasconcellos; F J Neves Mancuso; M M Noya Rabelo; M Rodrigues Bacci; F Santos; M Vidotti; M V Simões; R Preto; F L Gomes; C Vieira Nascimento; D Precoma; J A Ribas Fortes; P E Leães; J F Kerr Saraiva; F A Alves da Costa; G Reis; S Zieroth; D Dion; D Savard; R Bourgeois; C Constance; K Anderson; S Verma; M Leblanc; D Yung; E Swiggum; L Pliamm; B Tyrrell; T Huynh; J Spiegelman; N Giannetti; J Lavoie; M Hartleib; R Bhargava; L Straatman; S Virani; A Costa-Vitali; L Hill; M Heffernan; Y Khaykin; J Ricci; A Zhai; B Lubelsky; M Toma; L Yao; L Noronha; M Babapulle; A Pandey; G Curnew; J Berlingieri; S Kouz; E Lonn; R Chehayeb; Y Zheng; Y Sun; Z Fan; X Han; X Jiang; Q Tang; Z Zheng; J Zhang; Y Zhang; A Shen; J Yu; J Ye; Y Yao; J Yan; X Xu; J Ma; Y Li; S Li; S Lu; X Kong; G Yang; Z Yao; Y Pan; X Guo; Z Sun; Y Dong; D Peng; Z Yuan; J Lin; O Jerabek; H Burianova; T Fiala; J Hubac; O Ludka; P Vodnansky; K Zeman; D Foldyna; J Krupicka; L Busak; M Radvan; Z Vomacka; R Prosecky; R Cifkova; V Durdil; J Vesely; J Vaclavik; P Cervinka; A Linhart; T Brabec; R Miklik; E Bonnefoy Cudraz; A Jobbe Duval; D Tomasevic; G Habib; R Isnard; F Picard; P Khanoyan; J Dubois-Rande; M Galinier; F Roubille; J Alexandre; D Babuty; N Delarche; M Seronde; J Berneau; N Girerd; H Bourhaial; H Olbrich; S Genth-Zotz; E Kemala; B Lemke; M Böhm; S Schellong; W Rieker; M Faghih; A Birkenfeld; A Begemann; A Ghanem; A Ujeyl; S von Haehling; H Ince; T Dorsel; J Bauersachs; M Prull; H Darius; A Wilke; J Sauter; N Frey; C P Schulze; W König; L Maier; N Proskynitopoulos; H Ebert; H Sarnighausen; H Düngen; M Licka; N Marx; C Stellbrink; B Winkelmann; N Menck; L Koenyves; F Lakatos; A Matoltsy; E Noori; P Andrassy; S Kancz; G Simon; T Sydo; A Vorobcsuk; B Merkely; R Gabor Kiss; I Szakal; N Laszlo; T Barany; A Nagy; E Szolnoki; V Chopra; V Rastogi; B Shah; A Mullasari; J Shankar; V Mehta; A Oomman; T Nadu; U Kaul; S Komarlu; D Kahali; A Bhagwat; V Vijan; N Kamalakar Ghaisas; A Mehta; Y Kothari; S Taddei; M Scherillo; V Zacà; S Genovese; A Salvioni; A Fucili; F Fedele; F Cosmi; M Volpe; M Senni; C Mazzone; G Esposito; M Doi; H Yamamoto; S Sakagami; S Oishi; Y Yasaka; H Tsuboi; Y Fujino; S Matsuoka; Y Watanabe; T Himi; T Ide; M Ichikawa; Y Kijima; T Koga; S Yuda; K Fukui; T Kubota; M Manita; H Fujinaga; T Matsumura; Y Fukumoto; Y Kawai; G Hiasa; Y Kazatani; M Mori; A Ogimoto; M Inoko; M Oguri; M Kinoshita; K Okuhara; N Watanabe; Y Ono; K Otomo; Y Sato; T Matsunaga; A Takaishi; N Miyagi; H Uehara; H Takaishi; M Yagi; M Arikawa; T Hashizume; T Koizumi; K Nakayama; S Taguchi; M Nanasato; Y Yoshida; S Tsujiyama; T Nakamura; K Oku; M Shimizu; M Suwa; Y Momiyama; H Sugiyama; K Kobayashi; S Inoue; T Kadokami; K Maeno; K Kawamitsu; Y Maruyama; A Nakata; Y Shibata; A Wada; H Urata; T Kataoka; T Matsumoto; N Takahashi; M Imamaki; T Yoshitama; T Saito; H Sekino; Y Furutani; M Koda; T Shinozaki; K Hirabayashi; R Tsunoda; K Yonezawa; H Hori; G Llamas Esperon; J Illescas Díaz; P Fajardo; J Almeida Alvarado; A Bazzoni Ruiz; I Lopez Alcocer; L Valle Molina; C Hernandez Herrera; C Calvo Vargas; F G Padilla Padilla; I Rodriguez Briones; E Chuquiure Valenzuela; M Aguilera Real; J Carrillo Calvillo; M Alpizar Salaza; J Cervantes Escárcega; R Velasco Sanchez; N Al-Windy; L van Heerebeek; L Bellersen; H Brunner-La Rocca; J Post; G C M Linssen; M van de Wetering; R Peters; R van Stralen; R Groutars; P Smits; A Yilmaz; W E M Kok; P Van der Meer; P Dijkmans; R Troquay; A P van Alem; R Van de Wal; L Handoko; I C D Westendorp; P F M M van Bergen; B J W M Rensing; P Hoogslag; B Kietselaer; J A Kragten; F R den Hartog; L Danilowicz-Szymanowicz; G Raczak; W Piesiewicz; W Zmuda; W Kus; P Podolec; W Musial; G Drelich; G Kania; P Miekus; S Mazur; A Janik; J Spyra; J Peruga; P Balsam; B Krakowiak; J Szachniewicz; M Ginel; J Grzybowski; P Wojewoda; A Kalinka; A Zurakowski; R Koc; M Debinski; W Fil; M Kujawiak; J Forys; M Kasprzak; M Krol; P Michalski; E Mirek-Bryniarska; K Radwan; G Skonieczny; K Stania; G Skoczylas; A Madej; J Jurowiecki; B Firek; B Wozakowska-Kaplon; K Cymerman; H Cho; J Oh Na; B Yoo; J Choi; J Shin; M Cho; D Choi; S Hwan Han; J Jeong; J Kim; S Min Kang; D Kim; M Hyun Kim; J López-Sendón; L de la Fuente Galán; J Delgado Jiménez; N Manito Lorite; M Pérez de Juan Romero; F Cereto Castro; J González Juanatey; J Gómez; M Sanmartín Fernández; X Garcia-Moll Marimon; D Pascual Figal; R Bover Freire; M Saxena; Z Yousef; C Clifford; C Arden; A Bakhai; I Squire; G Jenkins; C Travill; D Price; J Neutel; K Adams; P Balfour; A Djamson; P Duncan; M Hong; S Woodhouse; R MacNevin; B Rama; C Broome-Webster; S Kindsvater; M Barettella; S Pinney; A Cohen; K Vora; K Challappa; S West; S Baum; J Cox; S Jani; A Karim; A Akhtar; R Goldberg; Z Bhatti; M Budoff; E Bush; A Potler; B Ellis; J Dy; J Fialkow; R Sangrigoli; K Ferdinand; C East; S Falkowski; S Donahoe; R Ebrahimi; G Kline; B Harris; R Khouzam; N Jaffrani; N Jarmukli; N Kazemi; M Koren; K Friedman; W Herzog; D Cheung; M Grover-McKay; P Hauptman; D Mikhalkova; S Khouri; F McGrew; P McCullough; R Littlefield; P Bradley; B McLaurin; S Lupovitch; I Labin; V Rao; M Leithe; N Lewis; D Lombardo; S Mahal; V Malhotra; I Dauber; A Banerjee; J Needell; G Miller; L Paladino; K Munuswamy; M Nanna; E McMillan; M Mumma; M Napoli; W Nelson; T O'Brien; A Adlakha; A Onwuanyi; H Serota; J Schmedtje; A Paraschos; R Potu; C Sai-Sudhakar; A Sauer; P Shah; H Skopicki; H Bui; K Carr; G Stevens; N Tahirkheli; J Tallaj; K Yousuf; B Trichon; J Welker; A Vest; X Wang; R Abadier; S Dunlap; N Weintraub; A Malik; P Kotha; V Zaha; G Kim; N Uriel; T Greene; A Salacata; R Arora; R Gazmuri; J Kobayashi; B Iteld; R Dab; Z Mirza; V Marques; M Nallasivan; H Saint-Jacques; K Barringhaus; J Contreras; A Gupta; S Koneru; V Nguyen
Contributors:	M., Packer; S. D., Anker; J., Butler; G., Filippato; S. J., Pocock; P., Carson; J., Januzzi; S., Verma; H., Tsutsui; M., Brueckmann; W., Jamal; K., Kimura; J., Schnee; C., Zeller; D., Cotton; E., Bocchi; M., Bohm; D. -J., Choi; V., Chopra; E., Chuquiure; N., Giannetti; S., Janssen; J., Zhang; J. R., Gonzalez Juanatey; S., Kaul; H. -P., Brunner-La Rocca; B., Merkely; S. J., Nicholl; S., Perrone; I., Pina; P., Ponikowski; N., Sattar; M., Senni; M. -F., Seronde; J., Spinar; I., Squire; S., Taddei; C., Wanner; F., Zannad; D Aizenberg, EMPEROR-Reduced Trial Investigators; Cartasegna, L; Colombo, H; Fernandez Moutin, M; Glenny, J; Alvarez Lorio, C; Anauch, D; Campos, R; Facta, A; Fernandez, A; Ahuad Guerrero, R; Lobo Márquez, L; A Leon de la Fuente, R; Mansilla, M; Hominal, M; Hasbani, E; Najenson, M; Luquez, H; Guzman, L; Sessa, H; Amuchástegui, M; Salomone, O; Perna, E; Piskorz, D; Sicer, M; Perez de Arenaza, D; Zaidman, C; Nani, S; Poy, C; Resk, J; Villarreal, R; Majul, C; Colombo Berra, F; Smith Casabella, T; Carnero, G; Caccavo, A; Berli, M; Budassi, N; Bono, J; Alvarisqueta, A; Amerena, J; Kostner, K; Hamilton, A; Begg, A; Colquhoun, D; Sverdlov, A; Vaddadi, G; Wong, J; Coller, J; Prior, D; Friart, A; Leone, A; Janssens, S; Vervoort, G; Timmermans, P; Sarens, T; Vandekerckhove, H; Van De Borne, P; Chenot, F; De Sutter, J; Z Maria Middelares, A
Publisher Information:	Massachussetts Medical Society; WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
Publication Year:	2020
Collection:	Sapienza Università di Roma: CINECA IRIS
Subject Terms:	Aged; Benzhydryl Compound; Cardiovascular Disease; Diabetes Mellitus; Type 2; Disease Progression; Double-Blind Method; Female; Glomerular Filtration Rate; Glucoside; Heart Failure; Hospitalization; Human; Male; Middle Aged; Proportional Hazards Model; Renal Insufficiency; Chronic; Sodium-Glucose Transporter 2 Inhibitor; Stroke Volume
Description:	BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODS In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTS During a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P
Document Type:	article in journal/newspaper
Language:	English
Relation:	info:eu-repo/semantics/altIdentifier/pmid/32865377; info:eu-repo/semantics/altIdentifier/wos/WOS:000579622800009; volume:383; issue:15; firstpage:1413; lastpage:1424; numberofpages:12; journal:NEW ENGLAND JOURNAL OF MEDICINE; http://hdl.handle.net/11573/1526264
DOI:	10.1056/NEJMoa2022190
Availability:	http://hdl.handle.net/11573/1526264; https://doi.org/10.1056/NEJMoa2022190
Accession Number:	edsbas.9F59E9DE
Database:	BASE